Department of Biotechnology and Medical Engineering, National Institute of Technology Rourkela, Rourkela 769008, Odisha, India.
Laboratory of Mycobacterial Immunology, Department of Life Science, National Institute of Technology Rourkela, Rourkela 769008, Odisha, India.
J Phys Chem B. 2024 Jun 27;128(25):5995-6013. doi: 10.1021/acs.jpcb.4c01578. Epub 2024 Jun 14.
Under the influence of various conditions, misfolding of soluble proteins occurs, leading to the formation of toxic insoluble amyloids. The formation and deposition of such amyloids within the body are associated with detrimental biological consequences such as the onset of several amyloid-related diseases. Previously, we established a strategy for the rational design of peptide inhibitors against amyloid formation based on the amyloidogenic-prone region of the protein. In the current study, we have designed and identified an Asp-containing rationally designed hexapeptide (SqP4) as an excellent inhibitor of hen egg-white lysozyme (HEWL) amyloid progression . First, SqP4 showed strong affinity toward the native monomeric HEWL leading to the stabilization of the native form and restriction in the unfolding process of monomeric HEWL. Second, SqP4 was found to arrest the amyloidogenic misfolded structure of HEWL in a nonfibrillar monomer-like stage. We also observed the differential effect of the protonation state of the charged amino acid (Asp) within the peptide inhibitor on the amyloid formation of HEWL and explored the reason behind the observations. The findings of this study can be implemented in future strategies for the development of potent therapeutics against other amyloid-related diseases.
在各种条件的影响下,可溶性蛋白质发生错误折叠,导致有毒的不溶性淀粉样蛋白的形成。这些淀粉样蛋白在体内的形成和沉积与有害的生物学后果有关,如几种淀粉样相关疾病的发作。此前,我们基于蛋白质的淀粉样形成倾向区域,建立了针对淀粉样形成的肽抑制剂的合理设计策略。在本研究中,我们设计并鉴定了一种含有天冬氨酸的合理设计的六肽(SqP4),作为鸡卵清溶菌酶(HEWL)淀粉样进展的优异抑制剂。首先,SqP4 对天然单体 HEWL 表现出很强的亲和力,导致天然形式的稳定和单体 HEWL 展开过程的限制。其次,发现 SqP4 可将 HEWL 的淀粉样错误折叠结构阻滞在非纤维状单体样阶段。我们还观察到肽抑制剂中天冬氨酸(Asp)的荷电氨基酸的质子化状态对 HEWL 淀粉样形成的差异影响,并探讨了观察结果背后的原因。本研究的结果可应用于未来针对其他淀粉样相关疾病的有效治疗药物的开发策略。